skip to main content

Thoracic Aortic Aneurysm — EECC MCQ

Instant feedback + full explanation. One question, done properly.

Hard"Cardiology"Thoracic Aortic AneurysmEECC

A patient with femoropopliteal peripheral arterial disease remains limited by claudication despite smoking cessation, secondary prevention and supervised exercise. Imaging and comorbidity review conclude that revascularisation is inappropriate. Which drug plan matches NICE guidance?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Offer naftidrofuryl, reviewing objective walking benefit after three to six months

NICE permits naftidrofuryl when supervised exercise has failed and revascularisation is unsuitable or declined, with discontinuation if meaningful benefit is absent after three to six months. Cilostazol, pentoxifylline and nicotinic acid are not the recommended vasoactive alternatives in this pathway. Full-dose anticoagulation is not a treatment for claudication walking limitation.

Reference: NICE CG147: Peripheral arterial disease — recommendations. https://www.nice.org.uk/guidance/cg147/chapter/recommendations